Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 1365441Generated: October 30, 2026

Hydrochloric Acid → (s)-1-(4-((2-(2,4-Dimethoxypyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one

https://huagongshe.com/reaction/1365441

Reaction equation

Participants

RoleNameHCIDCharge
ReactantHydrochloric AcidHCID 313—
ReactantL-Lactic AcidHCID 107689—
ReactantTert-butyl 4-((2-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylateHCID 56648760—
Reactant2-(2,4-Dimethoxypyrimidin-5-yl)-7-methyl-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidineHCID 66934269—
Product(s)-1-(4-((2-(2,4-Dimethoxypyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-oneHCID 24945989—

Reaction Steps

Tert-butyl 4-((2-chloro-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazine-1-carboxylate (75 mg) was reacted with 2,4-dimethoxypyrimidin-5-yl-5-boronic acid via General Procedure A. This crude intermediate was subjected to General Procedure D in which the crude HCl salt of 2-(2,4-dimethoxypyrimidin-5-yl)-7-methyl-4-morpholino-6-((piperazin-1-yl)methyl)thieno[3,2-d]pyrimidine was reacted with L-Lactic acid via General Procedure B to give 17.2 mg of 406 after reverse phase HPLC purification. MS (Q1) 544.2 (M)+.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS07888352B2
Source datasetuspto-grants-2011_02
ORD IDord-8baf4cfbc7114ca4be6fa16127cc4539
Source noteuspto-grants-2011_02